EPA en es it fr

EPA Brand names, EPA Analogs

EPA Brand Names Mixture

  • No information avaliable

EPA Chemical_Formula


EPA RX_link

No information avaliable

EPA fda sheet

EPA msds (material safety sheet)


EPA Synthesis Reference

No information avaliable

EPA Molecular Weight

302.456 g/mol

EPA Melting Point

No information avaliable

EPA H2O Solubility

No information avaliable

EPA State

Oily Liquid


6.23 +/- 0.48

EPA Dosage Forms

Capsule (usually in fish oil in a combination with DHA)

EPA Indication

EPA can be used for lowering elevated triglycerides in those who are hyperglyceridemic. In addition, EPA may play a therapeutic role in patients with cystic fibrosis by reducing disease severity and may play a similar role in type 2 diabetics in slowing the progression of diabetic nephropathy.

EPA Pharmacology

Eicosanoids are chemical messengers derived from 20-carbon polyunsaturated fatty acids that play critical roles in immune and inflammatory responses. Both 20-carbon omega-6 fatty acids (arachidonic acid) and 20-carbon omega-3 fatty acids (EPA) can be found in cell membranes. During an inflammatory response, arachidonic acid and EPA are metabolized by enzymes known as cyclooxygenases and lipoxygenases to form eicosanoids. Increasing omega-3 fatty acid intake increases the EPA content of cell membranes and decreases the arachidonic acid content, resulting in higher proportions of eicosanoids derived from EPA. Physiologic responses to arachidonic acid-derived eicosanoids differ from responses to EPA-derived eicosanoids. In general, eicosanoids derived from EPA are less potent inducers of inflammation, blood vessel constriction, and clotting than eicosanoids derived from arachidonic acid.

EPA Absorption

No information avaliable

EPA side effects and Toxicity

No information avaliable

EPA Patient Information

No information avaliable

EPA Organisms Affected

No information avaliable